KR20140015127A - 폴리머 입자 및 이의 용도 - Google Patents
폴리머 입자 및 이의 용도 Download PDFInfo
- Publication number
- KR20140015127A KR20140015127A KR1020127005296A KR20127005296A KR20140015127A KR 20140015127 A KR20140015127 A KR 20140015127A KR 1020127005296 A KR1020127005296 A KR 1020127005296A KR 20127005296 A KR20127005296 A KR 20127005296A KR 20140015127 A KR20140015127 A KR 20140015127A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- particle
- tuberculosis
- subject
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 392
- 239000002245 particle Substances 0.000 title claims abstract description 326
- 238000000034 method Methods 0.000 claims abstract description 197
- 230000001939 inductive effect Effects 0.000 claims abstract description 168
- 244000052769 pathogen Species 0.000 claims abstract description 91
- 230000021633 leukocyte mediated immunity Effects 0.000 claims abstract description 73
- 239000000427 antigen Substances 0.000 claims description 565
- 108091007433 antigens Proteins 0.000 claims description 564
- 102000036639 antigens Human genes 0.000 claims description 564
- 230000027455 binding Effects 0.000 claims description 329
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 307
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 301
- 229920001184 polypeptide Polymers 0.000 claims description 297
- 108090000623 proteins and genes Proteins 0.000 claims description 256
- 102000004169 proteins and genes Human genes 0.000 claims description 242
- 150000007523 nucleic acids Chemical group 0.000 claims description 218
- 230000004927 fusion Effects 0.000 claims description 211
- 230000014509 gene expression Effects 0.000 claims description 190
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 154
- 230000028993 immune response Effects 0.000 claims description 148
- 208000006454 hepatitis Diseases 0.000 claims description 132
- 231100000283 hepatitis Toxicity 0.000 claims description 132
- 206010022000 influenza Diseases 0.000 claims description 129
- 201000008827 tuberculosis Diseases 0.000 claims description 119
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 113
- 230000004044 response Effects 0.000 claims description 77
- 230000001717 pathogenic effect Effects 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 52
- 241000186359 Mycobacterium Species 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 26
- 239000000758 substrate Substances 0.000 claims description 21
- -1 MPT32 Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 230000003053 immunization Effects 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 17
- 241000606161 Chlamydia Species 0.000 claims description 15
- 241000589248 Legionella Species 0.000 claims description 15
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 15
- 102000004316 Oxidoreductases Human genes 0.000 claims description 15
- 108090000854 Oxidoreductases Proteins 0.000 claims description 15
- 108060008225 Thiolase Proteins 0.000 claims description 15
- 102000002932 Thiolase Human genes 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 108700026244 Open Reading Frames Proteins 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 12
- 241000712461 unidentified influenza virus Species 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 241000186781 Listeria Species 0.000 claims description 11
- 241000186366 Mycobacterium bovis Species 0.000 claims description 11
- 241000606701 Rickettsia Species 0.000 claims description 11
- 241000607142 Salmonella Species 0.000 claims description 11
- 230000028996 humoral immune response Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 108091007187 Reductases Proteins 0.000 claims description 9
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 208000007089 vaccinia Diseases 0.000 claims description 9
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 7
- 241000186779 Listeria monocytogenes Species 0.000 claims description 7
- 240000001341 Reynoutria japonica Species 0.000 claims description 7
- 241000606699 Rickettsia conorii Species 0.000 claims description 7
- 241000191940 Staphylococcus Species 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 241000589242 Legionella pneumophila Species 0.000 claims description 6
- 241000606697 Rickettsia prowazekii Species 0.000 claims description 6
- 241000607479 Yersinia pestis Species 0.000 claims description 6
- 230000008348 humoral response Effects 0.000 claims description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 6
- 241000193738 Bacillus anthracis Species 0.000 claims description 5
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 5
- 241000725619 Dengue virus Species 0.000 claims description 5
- 241000605314 Ehrlichia Species 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 claims description 5
- 241000186362 Mycobacterium leprae Species 0.000 claims description 5
- 241000606723 Rickettsia akari Species 0.000 claims description 5
- 241000606720 Rickettsia australis Species 0.000 claims description 5
- 241000606726 Rickettsia typhi Species 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 5
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 4
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 4
- 241000186367 Mycobacterium avium Species 0.000 claims description 4
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 4
- 241001631646 Papillomaviridae Species 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 4
- 241000606695 Rickettsia rickettsii Species 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 241000710886 West Nile virus Species 0.000 claims description 4
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 4
- 229940065181 bacillus anthracis Drugs 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 4
- 241000606678 Coxiella burnetii Species 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000605310 Ehrlichia chaffeensis Species 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000589244 Fluoribacter bozemanae Species 0.000 claims description 3
- 241000228402 Histoplasma Species 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 241001137872 Leishmania sp. Species 0.000 claims description 3
- 241001495403 Rickettsia africae Species 0.000 claims description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 241000710961 Semliki Forest virus Species 0.000 claims description 3
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 3
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 3
- 241000607477 Yersinia pseudotuberculosis Species 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 claims description 2
- 241000605281 Anaplasma phagocytophilum Species 0.000 claims description 2
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 claims description 2
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 101710088427 Diacylglycerol acyltransferase/mycolyltransferase Ag85C Proteins 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 101100291912 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb64 gene Proteins 0.000 claims description 2
- 101001043272 Mycobacterium tuberculosis (strain ATCC 25177 / H37Ra) Lipoprotein LpqH Proteins 0.000 claims description 2
- 101000856404 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Carboxylesterase Culp1 Proteins 0.000 claims description 2
- 101000941208 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Probable carboxylesterase Culp2 Proteins 0.000 claims description 2
- 101100385666 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cut7 gene Proteins 0.000 claims description 2
- 101100274117 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) groEL2 gene Proteins 0.000 claims description 2
- 101100395578 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hrp1 gene Proteins 0.000 claims description 2
- 101150009192 PPE68 gene Proteins 0.000 claims description 2
- 101150056612 PPIA gene Proteins 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 101710181935 Phosphate-binding protein PstS 1 Proteins 0.000 claims description 2
- 101710181937 Phosphate-binding protein PstS 2 Proteins 0.000 claims description 2
- 101710181936 Phosphate-binding protein PstS 3 Proteins 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 101150027583 cfp32 gene Proteins 0.000 claims description 2
- 101150001139 cfp6 gene Proteins 0.000 claims description 2
- 101150069551 esxH gene Proteins 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 101150007644 hspX gene Proteins 0.000 claims description 2
- 101150047914 mpt51 gene Proteins 0.000 claims description 2
- 101150076681 mpt63 gene Proteins 0.000 claims description 2
- 101150014428 mpt64 gene Proteins 0.000 claims description 2
- 101150023079 mpt83 gene Proteins 0.000 claims description 2
- 101150009453 mtc28 gene Proteins 0.000 claims description 2
- 229960001005 tuberculin Drugs 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 4
- 241000709664 Picornaviridae Species 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 102000006303 Chaperonin 60 Human genes 0.000 claims 1
- 241000726306 Irus Species 0.000 claims 1
- 108700020164 Mycobacterium tuberculosis ESAT-6 Proteins 0.000 claims 1
- 239000012645 endogenous antigen Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 207
- 241000589516 Pseudomonas Species 0.000 description 96
- 102000040430 polynucleotide Human genes 0.000 description 67
- 108091033319 polynucleotide Proteins 0.000 description 67
- 239000002157 polynucleotide Substances 0.000 description 67
- 125000003275 alpha amino acid group Chemical group 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 28
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 230000001404 mediated effect Effects 0.000 description 26
- 241000193830 Bacillus <bacterium> Species 0.000 description 20
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 20
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 125000005647 linker group Chemical group 0.000 description 18
- 125000006850 spacer group Chemical group 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 108010010718 poly(3-hydroxyalkanoic acid) synthase Proteins 0.000 description 13
- 241000588986 Alcaligenes Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 10
- 241000589562 Brucella Species 0.000 description 9
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 9
- 241000194107 Bacillus megaterium Species 0.000 description 8
- 241000589776 Pseudomonas putida Species 0.000 description 8
- 241000191025 Rhodobacter Species 0.000 description 8
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 8
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 241000589291 Acinetobacter Species 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010019799 Hepatitis viral Diseases 0.000 description 7
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 7
- 241000405217 Viola <butterfly> Species 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 201000001862 viral hepatitis Diseases 0.000 description 7
- 241000589158 Agrobacterium Species 0.000 description 6
- 241001453380 Burkholderia Species 0.000 description 6
- 240000000533 Capsicum pubescens Species 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 241001528539 Cupriavidus necator Species 0.000 description 6
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 241000188645 Pseudogulbenkiania ferrooxidans Species 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000589567 Brucella abortus Species 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 5
- 241000589781 Pseudomonas oleovorans Species 0.000 description 5
- 241000232299 Ralstonia Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000607528 Aeromonas hydrophila Species 0.000 description 4
- 241000611270 Alcanivorax borkumensis Species 0.000 description 4
- 241000190857 Allochromatium vinosum Species 0.000 description 4
- 241000726110 Azoarcus Species 0.000 description 4
- 241000894008 Azorhizobium Species 0.000 description 4
- 241000020731 Burkholderia multivorans Species 0.000 description 4
- 244000068645 Carya illinoensis Species 0.000 description 4
- 235000009025 Carya illinoensis Nutrition 0.000 description 4
- 241001600125 Delftia acidovorans Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000190986 Ectothiorhodospira Species 0.000 description 4
- 241001509401 Gordonia rubripertincta Species 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241000589323 Methylobacterium Species 0.000 description 4
- 241001057811 Paracoccus <mealybug> Species 0.000 description 4
- 241000589755 Pseudomonas mendocina Species 0.000 description 4
- 241000520900 Pseudomonas resinovorans Species 0.000 description 4
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 4
- 241000190984 Rhodospirillum rubrum Species 0.000 description 4
- 241000192584 Synechocystis Species 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- 241000190999 Thiococcus pfennigii Species 0.000 description 4
- 241000607598 Vibrio Species 0.000 description 4
- 241000607626 Vibrio cholerae Species 0.000 description 4
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229910000085 borane Inorganic materials 0.000 description 4
- 210000004900 c-terminal fragment Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000000078 claw Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000011021 lapis lazuli Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000589568 Brucella ovis Species 0.000 description 3
- 241001647373 Chlamydia abortus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000589519 Comamonas Species 0.000 description 3
- 241001137853 Crenarchaeota Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000589601 Francisella Species 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 206010024229 Leprosy Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241001645955 Pseudomonas chlororaphis subsp. aureofaciens Species 0.000 description 3
- 241000589614 Pseudomonas stutzeri Species 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 244000052637 human pathogen Species 0.000 description 3
- 238000012296 in situ hybridization assay Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 2
- 241000607516 Aeromonas caviae Species 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 241000864489 Alcanivorax borkumensis SK2 Species 0.000 description 2
- 241001655243 Allochromatium Species 0.000 description 2
- 241000133676 Aspergillus latus Species 0.000 description 2
- 241000193033 Azohydromonas lata Species 0.000 description 2
- 241001148106 Brucella melitensis Species 0.000 description 2
- 241001148112 Brucella neotomae Species 0.000 description 2
- 241001148111 Brucella suis Species 0.000 description 2
- 241000589513 Burkholderia cepacia Species 0.000 description 2
- 241000863012 Caulobacter Species 0.000 description 2
- 241000010804 Caulobacter vibrioides Species 0.000 description 2
- 241001647378 Chlamydia psittaci Species 0.000 description 2
- 241000588881 Chromobacterium Species 0.000 description 2
- 241000588879 Chromobacterium violaceum Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241001600129 Delftia Species 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000191004 Ectothiorhodospira shaposhnikovii Species 0.000 description 2
- 208000031912 Endemic Flea-Borne Typhus Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000968725 Gammaproteobacteria bacterium Species 0.000 description 2
- 241001337904 Gordonia <angiosperm> Species 0.000 description 2
- 241000205063 Haloarcula marismortui Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000589264 Legionella longbeachae Species 0.000 description 2
- 241000890160 Limnobacter Species 0.000 description 2
- 206010024641 Listeriosis Diseases 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000543670 Magnetospirillum gryphiswaldense Species 0.000 description 2
- 241000426386 Marinobacter algicola DG893 Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000589308 Methylobacterium extorquens Species 0.000 description 2
- 241001430258 Methylobacterium radiotolerans Species 0.000 description 2
- 206010028282 Murine typhus Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 241001135514 Paraburkholderia caryophylli Species 0.000 description 2
- 241000008865 Paraburkholderia denitrificans Species 0.000 description 2
- 241001086828 Paracoccus seriniphilus Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000204735 Pseudomonas nitroreducens Species 0.000 description 2
- 241000589630 Pseudomonas pseudoalcaligenes Species 0.000 description 2
- 240000008493 Psychotria punctata Species 0.000 description 2
- 241000589771 Ralstonia solanacearum Species 0.000 description 2
- 241000589180 Rhizobium Species 0.000 description 2
- 241000589194 Rhizobium leguminosarum Species 0.000 description 2
- 101100297400 Rhizobium meliloti (strain 1021) phaAB gene Proteins 0.000 description 2
- 241000191023 Rhodobacter capsulatus Species 0.000 description 2
- 241001524101 Rhodococcus opacus Species 0.000 description 2
- 244000281247 Ribes rubrum Species 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241001135312 Sinorhizobium Species 0.000 description 2
- 241000589196 Sinorhizobium meliloti Species 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241001464942 Thauera Species 0.000 description 2
- 241000191001 Thiocapsa Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 241000589651 Zoogloea Species 0.000 description 2
- 241000589153 Zoogloea ramigera Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940056450 brucella abortus Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000004883 computer application Methods 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 201000005901 endemic typhus Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002873 global sequence alignment Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940115932 legionella pneumophila Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 229940046939 rickettsia prowazekii Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 201000004284 spotted fever Diseases 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 201000009133 African tick-bite fever Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000588813 Alcaligenes faecalis Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000980809 Aspergillus aureus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 206010006045 Boutonneuse fever Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241000514715 Brucella pinnipedialis Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241001478312 Comamonas sp. Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283087 Equus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000004204 Fascin Human genes 0.000 description 1
- 108090000786 Fascin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 208000035353 Legionnaires disease Diseases 0.000 description 1
- 241001478273 Leptothrix sp. (in: Bacteria) Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000037482 Microtea Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000187919 Mycobacterium microti Species 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001148116 Paucimonas lemoignei Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035718 Pneumonia legionella Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 101100463818 Pseudomonas oleovorans phaC1 gene Proteins 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 241000589625 Ralstonia pickettii Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 201000004282 Rickettsialpox Diseases 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 201000008497 Siberian tick typhus Diseases 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101100280476 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) fabM gene Proteins 0.000 description 1
- 241000187439 Streptomyces exfoliatus Species 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241001454746 Streptomyces niveus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940059720 apra Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 101150046540 phaA gene Proteins 0.000 description 1
- 101150110984 phaB gene Proteins 0.000 description 1
- 101150048611 phaC gene Proteins 0.000 description 1
- 101150092627 phaF gene Proteins 0.000 description 1
- 101150028013 phaP gene Proteins 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22934809P | 2009-07-29 | 2009-07-29 | |
| US22931809P | 2009-07-29 | 2009-07-29 | |
| US61/229,318 | 2009-07-29 | ||
| US61/229,348 | 2009-07-29 | ||
| PCT/IB2010/053465 WO2011013097A2 (en) | 2009-07-29 | 2010-07-29 | Polymer particles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140015127A true KR20140015127A (ko) | 2014-02-06 |
Family
ID=43529777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127005296A Ceased KR20140015127A (ko) | 2009-07-29 | 2010-07-29 | 폴리머 입자 및 이의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20120201846A1 (enExample) |
| EP (1) | EP2461822A4 (enExample) |
| JP (1) | JP2013500329A (enExample) |
| KR (1) | KR20140015127A (enExample) |
| CN (2) | CN102573891B (enExample) |
| AU (1) | AU2010277222A1 (enExample) |
| CA (1) | CA2769645A1 (enExample) |
| EA (1) | EA201290072A1 (enExample) |
| SG (1) | SG178144A1 (enExample) |
| WO (1) | WO2011013097A2 (enExample) |
| ZA (1) | ZA201201482B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102180974B (zh) * | 2011-03-22 | 2013-12-11 | 兰州大学 | 一种结核杆菌融合蛋白及其制备方法和应用 |
| US9926346B2 (en) | 2012-04-16 | 2018-03-27 | Aeras | Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof |
| WO2013190453A2 (en) * | 2012-06-18 | 2013-12-27 | Tracy Thompson | Compositions for separation methods |
| CN102716474B (zh) * | 2012-06-27 | 2013-10-16 | 中国人民解放军军事医学科学院微生物流行病研究所 | 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用 |
| WO2014016362A1 (en) * | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| US20140073022A1 (en) * | 2012-09-10 | 2014-03-13 | Wisconsin Alumni Research Foundation | Production of polyhydroxyalkanoates with a defined composition from an unrelated carbon source |
| WO2015119512A1 (en) * | 2014-02-04 | 2015-08-13 | Bernd Helmut Adam Rehm | Polymer particles and uses thereof |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| WO2016142681A1 (en) | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Spectrometric analysis of microbes |
| EP3726562B1 (en) | 2015-03-06 | 2023-12-20 | Micromass UK Limited | Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue |
| US10777398B2 (en) | 2015-03-06 | 2020-09-15 | Micromass Uk Limited | Spectrometric analysis |
| US11139156B2 (en) | 2015-03-06 | 2021-10-05 | Micromass Uk Limited | In vivo endoscopic tissue identification tool |
| GB2556994B (en) | 2015-03-06 | 2021-05-12 | Micromass Ltd | Identification of bacterial strains in biological samples using mass spectrometry |
| GB2556436B (en) | 2015-03-06 | 2022-01-26 | Micromass Ltd | Cell population analysis |
| WO2016142691A1 (en) * | 2015-03-06 | 2016-09-15 | Micromass Uk Limited | Rapid evaporative ionisation mass spectrometry ("reims") and desorption electrospray ionisation mass spectrometry ("desi-ms") analysis of swabs and biopsy samples |
| EP3316905A1 (en) | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| WO2017178833A1 (en) | 2016-04-14 | 2017-10-19 | Micromass Uk Limited | Spectrometric analysis of plants |
| US11801290B2 (en) | 2016-09-16 | 2023-10-31 | Access To Advanced Health Institute | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
| JP7313345B2 (ja) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | デング熱に対するブースターワクチン接種のための組成物 |
| KR102107519B1 (ko) * | 2018-06-25 | 2020-05-07 | 경상대학교산학협력단 | 브루셀라 어보투스 균주 유래의 InpB, Dps, AspC 및 Ndk 단백질을 유효성분으로 포함하는 브루셀라 감염증 예방 또는 치료용 백신 조성물 |
| KR102317403B1 (ko) * | 2019-01-28 | 2021-10-29 | 주식회사 바이오앱 | 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 |
| CN109813884A (zh) * | 2019-03-25 | 2019-05-28 | 中国动物卫生与流行病学中心 | 一种牛结核病γ-干扰素快速检测制品 |
| CN110411907B (zh) * | 2019-06-19 | 2020-05-22 | 上海交通大学 | 植物叶片上亚微米颗粒物凝并效率测定方法、系统及介质 |
| GB201913716D0 (en) * | 2019-09-24 | 2019-11-06 | Imp College Innovations Ltd | Methods |
| JP7584763B2 (ja) * | 2020-06-04 | 2024-11-18 | 東亞合成株式会社 | 抗ウイルス性ペプチドおよびその利用 |
| CN117430664B (zh) * | 2023-10-24 | 2024-04-09 | 暨南大学附属第六医院(东莞市东部中心医院) | 一种甲型流感病毒t细胞抗原表位肽及其应用 |
| CN118085043B (zh) * | 2024-04-17 | 2024-07-19 | 成都康华生物制品股份有限公司 | 结核分枝杆菌多免疫原抗原、编码其的多核苷酸、应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| EP0175261B1 (en) * | 1984-09-12 | 1991-12-11 | Chiron Corporation | Hybrid particle immunogens |
| ES2291810T3 (es) * | 1997-04-02 | 2008-03-01 | Statens Serum Institut | Fragmentos de acido nucleico y fragmentos de polpeptidos derivados de m. tuberculosis. |
| US6982085B2 (en) * | 1997-04-02 | 2006-01-03 | Statens Serum Institut | TB diagnostic based on antigens from M. tuberculosis |
| AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| EP1523331B1 (en) * | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
| DE10240035A1 (de) * | 2002-08-30 | 2004-03-11 | Rehm, Bernd H.A., PD Dr.rer.nat. | Biogene Polyester-Partikel definierter Größe mit funktionalisierten Oberflächen:Herstellungsverfahren und pharmazeutische Zubereitungen, in denen diese enthalten sind |
| CA2528007C (en) * | 2003-06-02 | 2012-03-27 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
| AU2006261445B2 (en) * | 2005-06-23 | 2011-03-31 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| DK1929010T3 (en) * | 2005-09-27 | 2014-03-10 | Polybatics Ltd | Use of the polymer particles |
| CN100518821C (zh) * | 2006-09-14 | 2009-07-29 | 复旦大学 | Ag85B,ESAT-6的嵌合疫苗 |
-
2010
- 2010-07-29 WO PCT/IB2010/053465 patent/WO2011013097A2/en not_active Ceased
- 2010-07-29 SG SG2012006193A patent/SG178144A1/en unknown
- 2010-07-29 JP JP2012522328A patent/JP2013500329A/ja active Pending
- 2010-07-29 AU AU2010277222A patent/AU2010277222A1/en not_active Abandoned
- 2010-07-29 KR KR1020127005296A patent/KR20140015127A/ko not_active Ceased
- 2010-07-29 CN CN201080043214.7A patent/CN102573891B/zh not_active Expired - Fee Related
- 2010-07-29 EP EP10803995.9A patent/EP2461822A4/en not_active Withdrawn
- 2010-07-29 US US13/387,739 patent/US20120201846A1/en not_active Abandoned
- 2010-07-29 CN CN201610287281.2A patent/CN106421743A/zh active Pending
- 2010-07-29 EA EA201290072A patent/EA201290072A1/ru unknown
- 2010-07-29 CA CA2769645A patent/CA2769645A1/en not_active Abandoned
-
2012
- 2012-02-28 ZA ZA2012/01482A patent/ZA201201482B/en unknown
-
2015
- 2015-10-29 US US14/927,321 patent/US20160175419A1/en not_active Abandoned
-
2017
- 2017-03-08 US US15/453,073 patent/US20180015156A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011013097A3 (en) | 2011-04-07 |
| US20120201846A1 (en) | 2012-08-09 |
| WO2011013097A2 (en) | 2011-02-03 |
| EP2461822A2 (en) | 2012-06-13 |
| US20160175419A1 (en) | 2016-06-23 |
| ZA201201482B (en) | 2012-11-28 |
| JP2013500329A (ja) | 2013-01-07 |
| EA201290072A1 (ru) | 2012-12-28 |
| CN106421743A (zh) | 2017-02-22 |
| US20180015156A1 (en) | 2018-01-18 |
| CN102573891B (zh) | 2016-06-01 |
| CN102573891A (zh) | 2012-07-11 |
| EP2461822A4 (en) | 2013-07-17 |
| SG178144A1 (en) | 2012-03-29 |
| CA2769645A1 (en) | 2011-02-03 |
| AU2010277222A1 (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20140015127A (ko) | 폴리머 입자 및 이의 용도 | |
| AU2019279084B2 (en) | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy | |
| AU2019203955B2 (en) | Multipartite signaling proteins and uses thereof | |
| KR102787119B1 (ko) | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 | |
| CN114058604B (zh) | 一种融合蛋白及其在碱基编辑中的用途 | |
| RU2761631C2 (ru) | Белки rsv в предшествующей слиянию конформации и их применение | |
| US6420524B1 (en) | Gain of function mutations in ATP-dependent transposition proteins | |
| KR20210080375A (ko) | 암 면역요법을 위한 재조합 폭스바이러스 | |
| KR20120136349A (ko) | 고가의 화학적 생성물의 미생물 생산, 및 관련 조성물, 방법 및 시스템 | |
| KR20140015136A (ko) | 3-히드록시프로피온산 및 다른 생성물의 제조 방법 | |
| AU2018386002B2 (en) | CAS9 variants and methods of use | |
| MXPA03009632A (es) | Proteinas de la envoltura de vhc glucosiladas en la estructura central. | |
| CN114222763A (zh) | 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点 | |
| CN111867637B (zh) | 新ehv插入位点ul43 | |
| KR20230134524A (ko) | 무장된 세네카 밸리 바이러스 종양용해 요법 조성물및 그의 방법 | |
| BRPI0618672A2 (pt) | bactérias e composições pró-apoptóticas para a distribuição e a expressão de antìgenos | |
| CN112608932A (zh) | 一种大肠杆菌中高效表达禽腺病毒Fiber-2蛋白的方法 | |
| CN100475964C (zh) | Hcv复制子穿梭载体 | |
| US20230149526A1 (en) | Combinations of flavivirus proteins, peptide sequences, epitopes, and methods and uses thereof | |
| CN113025638B (zh) | 一种基于双链核酸的折纸结构及其制备方法和应用 | |
| US11814412B2 (en) | Artificial proteins and compositions and methods thereof | |
| CN116322793A (zh) | 改进的使用科卡尔包膜的t细胞转导用慢病毒载体的生成 | |
| KR20150100606A (ko) | 아테리바이러스 단백질 및 발현 메커니즘 | |
| CN116555335A (zh) | 一种可调节的先导编辑器及其应用 | |
| KR20230112625A (ko) | 나이세리아 고노레아에 대한 백신접종을 위한 조성물 및 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20120228 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20150724 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161118 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170418 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20161118 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |